报价延迟最少15分钟:2025/11/15 03:04 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
15.6 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.86/1.05
|
|
企业价值
10.30B
|
| 资产负债 |
|
每股账面净值
18.15
|
| 现金流量 |
|
现金流量率
0.03
|
| 损益表 |
|
收益
4.79B
|
|
每股收益
11.21
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/11/15 03:04 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
